Pharmacotherapy for pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) first entered the health care market in the United States on July 16, 2012 when the US Food and Drug Administration (FDA) approved emtricitabine/tenofovir disoproxil fumarate (FTC/